Practical approach in hepatitis b e antigen-negative individuals to identify treatment candidates

被引:0
作者
Ahmad Najib Azmi [1 ]
Soek-Siam Tan [2 ]
Rosmawati Mohamed [3 ]
机构
[1] Faculty of Medicine and Health Sciences,Universiti Sains Islam Malaysia,55100 Kuala Lumpur,Malaysia
[2] Department of Hepatology,Selayang Hospital,68100 Selangor,Malaysia  3. Department of Medicine,Faculty of Medicine,University of Malaya,50603 Kuala Lumpur,Malaysia
关键词
Chronic hepatitis B; Hepatitis B e antigennegative; Treatment candidates; Hepatitis B s antigen level; Nucleos(t)ides analogues; Pegylated interferon;
D O I
暂无
中图分类号
R512.62 [];
学科分类号
100401 ;
摘要
The natural history of chronic hepatitis B is characterized by different phases of infection,and patients may evolve from one phase to another or may revert to a previous phase.The hepatitis B e antigen(HBeAg)-negative form is the predominant infection worldwide,which consists of individuals with a range of viral replication and liver disease severity.Although alanine transaminase(ALT)remains the most accessible test available to clinicians for monitoring the liver disease status,further evaluations are required for some patients to assess if treatment is warranted.Guidance from practice guidelines together with thorough investigations and classifications of patients ensure recognition of who needs which level of care.This article aims to assist physicians in the assessment of HBeAgnegative individuals using liver biopsy or non-invasive tools such as hepatitis B s antigen quantification and transient elastography in addition to ALT and hepatitis B virus DNA,to identify who will remain stable,who will reactivate or at risk of disease progression hence will benefit from timely initiation of anti-viral therapy.
引用
收藏
页码:12045 / 12055
页数:11
相关论文
共 11 条
[1]  
Hepatitis B:Epidemiology and prevention in developing countries[J]. Elisabetta Franco,Barbara Bagnato,Maria Giulia Marino,Cristina Meleleo,Laura Serino,Laura Zaratti. World Journal of Hepatology. 2012(03)
[2]   Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients [J].
Jeng, Wen-Juei ;
Sheen, I-Shyan ;
Chen, Yi-Cheng ;
Hsu, Chao-Wei ;
Chien, Rong-Nan ;
Chu, Chia-Ming ;
Liaw, Yun-Fan .
HEPATOLOGY, 2013, 58 (06) :1888-1896
[3]   Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA [J].
Martinot-Peignoux, Michelle ;
Lapalus, Martine ;
Laouenan, Cedric ;
Lada, Olivier ;
Netto-Cardoso, Ana Carolina Ferreira ;
Boyer, Nathalie ;
Ripault, Marie Pierre ;
Carvalho-Filho, Roberto ;
Asselah, Tarik ;
Marcellin, Patrick .
JOURNAL OF CLINICAL VIROLOGY, 2013, 58 (02) :401-407
[4]   Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B [J].
Sonneveld, Milan J. ;
Rijckborst, Vincent ;
Zeuzem, Stefan ;
Heathcote, E. Jenny ;
Simon, Krzysztof ;
Senturk, Hakan ;
Pas, Suzan D. ;
Hansen, Bettina E. ;
Janssen, Harry L. A. .
HEPATOLOGY, 2012, 56 (01) :67-75
[5]   Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B [J].
Chang, Ting-Tsung ;
Liaw, Yun-Fan ;
Wu, Shun-Sheng ;
Schiff, Eugene ;
Han, Kwang-Hyub ;
Lai, Ching-Lung ;
Safadi, Rifaat ;
Lee, Samuel S. ;
Halota, Waldemar ;
Goodman, Zachary ;
Chi, Yun-Chan ;
Zhang, Hui ;
Hindes, Robert ;
Iloeje, Uchenna ;
Beebe, Suzanne ;
Kreter, Bruce .
HEPATOLOGY, 2010, 52 (03) :886-893
[6]   Lamivudine Maintenance Beyond One Year After HBeAg Seroconversion Is a Major Factor for Sustained Virologic Response in HBeAg-Positive Chronic Hepatitis B [J].
Lee, Hyun Woong ;
Lee, Heon Ju ;
Hwang, Jae Seok ;
Sohn, Joo Hyun ;
Jang, Jae Young ;
Han, Ki Jun ;
Park, Jun Yong ;
Kim, Do Young ;
Ahn, Sang Hoon ;
Paik, Yong Han ;
Lee, Chun Kyon ;
Lee, Kwan Sik ;
Chon, Chae Yoon ;
Han, Kwang-Hyub .
HEPATOLOGY, 2010, 51 (02) :415-421
[7]  
Chronic hepatitis B: Update 2009[J] . Anna S. F. Lok,Brian J. McMahon. Hepatology . 2009 (3)
[8]  
Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time[J] . Dar‐In Tai,Shi‐Ming Lin,I‐Shyan Sheen,Chia‐Ming Chu,Deng‐Yn Lin,Yun‐Fan Liaw. Hepatology . 2009 (6)
[9]  
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B[J] . Maurizia Rossana Brunetto,Francesco Moriconi,Ferruccio Bonino,George K. K. Lau,Patrizia Farci,Cihan Yurdaydin,Teerha Piratvisuth,Kangxian Luo,Yuming Wang,Stephanos Hadziyannis,Eva Wolf,Philip McCloud,Richard Batrla,Patrick Marcellin. Hepatology . 2009 (4)
[10]  
Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine[J] . George V. Papatheodoridis,Evangelini Dimou,Konstantinos Dimakopoulos,Spilios Manolakopoulos,Irene Rapti,George Kitis,Dimitrios Tzourmakliotis,Emanuel Manesis,Stephanos J. Hadziyannis. Hepatology . 2005 (1)